Posted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed this treatment with a view to registering it for reimbursement under common law and has decided in favour.
The HAS had granted, as of January 22, early access to Paxlovid (nirmatrelvir with ritonavir) from Pfizer for adults with COVID-19 not requiring oxygen therapy and at high risk of progression to a severe form of the disease.
Today, the HAS is issuing a favourable opinion on registration for reimbursement of this treatment in this same indication.
